Results 221 to 230 of about 16,747 (255)
Some of the next articles are maybe not open access.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
openaire +2 more sources
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
openaire +2 more sources
Pediatric Infectious Disease Journal, 2011
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Thomas J. Walsh, Jill A. Hoffman
openaire +2 more sources
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Thomas J. Walsh, Jill A. Hoffman
openaire +2 more sources
Echinocandins: production and applications
Applied Microbiology and Biotechnology, 2013The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi.
Emri, Tamás +3 more
openaire +3 more sources
Echinocandins in Ocular Therapeutics
Journal of Ocular Pharmacology and Therapeutics, 2017Fungal infections of the eye, especially fungal keratitis and endophthalmitis, are major causes of concern and if left untreated could lead to vision loss. Currently, natamycin (polyene antifungal) is the only commercially available topical agent used for the treatment of ocular fungal infections.
Akash Patil, Soumyajit Majumdar
openaire +3 more sources